Research programme: CD26 antigen antagonists - PfizerAlternative Names: DP-893
Latest Information Update: 03 Aug 2009
At a glance
- Originator Pfizer
- Class Antihyperglycaemics; Pyrrolidines; Sulfonamides
- Mechanism of Action CD26 antigen inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Type 2 diabetes mellitus